These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 29702784)

  • 1. The Update of the Mexican Health Care Formulary and Supply Catalog in the Context of the Health Technology Assessment.
    Ríos PR; Rivera AG; Oropeza IR; Ramírez OC
    Value Health Reg Issues; 2014 Dec; 5():29-34. PubMed ID: 29702784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criterios Farmacoeconómicos Usados en México para la Evaluación de Tratamientos en Personas en Fases Terminales.
    Rizo Ríos P; González Rivera A; Campos Ramírez O; Lifshitz Guinzberg A
    Value Health Reg Issues; 2012 Dec; 1(2):264-266. PubMed ID: 29702912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Not Available].
    Ríos PR; Rivera AG; Oropeza IR; Rivas Bocanegra RE
    Value Health Reg Issues; 2013 Dec; 2(3):387-391. PubMed ID: 29702775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based clinical guidelines in Kyrgyz Republic.
    Zurdinova AA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S45-6. PubMed ID: 26639705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health technology reassessment in the Brazilian public health system: Analysis of the current status.
    Pereira VC; Barreto JOM; Neves FADR
    PLoS One; 2019; 14(7):e0220131. PubMed ID: 31356609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women--the underused human resource: education and training of women for community participation.
    Elmendorf ML
    Educ Med Salud; 1982; 16(4):463-83. PubMed ID: 7169050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.
    Carroll C; Kaltenthaler E; FitzGerald P; Boland A; Dickson R
    Health Policy; 2011 Oct; 102(2-3):136-44. PubMed ID: 21763025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National tuberculosis programme review: experience over the period 1990-95.
    Pio A; Luelmo F; Kumaresan J; Spinaci S
    Bull World Health Organ; 1997; 75(6):569-81. PubMed ID: 9509630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Institutionalising health technology assessment: establishing the Medical Technology Assessment Board in India.
    Downey LE; Mehndiratta A; Grover A; Gauba V; Sheikh K; Prinja S; Singh R; Cluzeau FA; Dabak S; Teerawattananon Y; Kumar S; Swaminathan S
    BMJ Glob Health; 2017; 2(2):e000259. PubMed ID: 29225927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision-Oriented Health Technology Assessment: One Step Forward in Supporting the Decision-Making Process in Hospitals.
    Ritrovato M; Faggiano FC; Tedesco G; Derrico P
    Value Health; 2015 Jun; 18(4):505-11. PubMed ID: 26091605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.